Clinical Trial Update: Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating valganciclovir to prevent cytomegalovirus infection in kidney and kidney/pancreas transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection
• Kidney Transplantation
• Pancreas Transplantation

Drugs mentioned

• Valcyte (valganciclovir)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Kidney Trasplant | Phase 4 | Status: COMPLETED